Biological characterization of rodent and human vasopressin V1breceptors using SSR-149415, a nonpeptide V1breceptor ligand

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302 · see citing works

Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922 · see citing works

Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin

Gillies, G. E., Linton, E. A., & Lowry, P. J. (1982) · Nature · doi:10.1038/299355a0 · Cited by 965 · see citing works

Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity

Urlaub, G., & Chasin, L. A. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.7.4216 · Cited by 876 · see citing works

Association of β-Arrestin with G Protein-coupled Receptors during Clathrin-mediated Endocytosis Dictates the Profile of Receptor Resensitization

Oakley, R. H., Laporte, S. A., Holt, J. A., Barak, L. S., & Caron, M. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32248 · Cited by 567 · see citing works

Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants

Morello, J.-P., Salahpour, A., Laperrière, A., Bernier, V., Arthus, M., Lonergan, M., Petäjä‐Repo, U. E., Angers, S., Morin, D., Bichet, D. G., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8688 · Cited by 558 · see citing works

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V _1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders

Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471 · see citing works

Localization and pharmacological characterization of high affinity binding sites for vasopressin and oxytocin in the rat brain by light microscopic autoradiography

Tribollet, E., Barberis, C., Jard, S., Dubois-Dauphin, M., & Dreifuss, J. J. (1988) · Brain Research · doi:10.1016/0006-8993(88)91437-0 · Cited by 442 · see citing works

Interaction of Corticotropin-Releasing Factor and Arginine Vasopressin on Adrenocorticotropin Secretion in Vivo *

RIVIER, C. L., & Vale, W. (1983) · Endocrinology · doi:10.1210/endo-113-3-939 · Cited by 409 · see citing works

Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor.

Sugimoto, T., Saito, M., Mochizuki, S., Watanabe, Y., Hashimoto, S., & Kawashima, H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47129-3 · Cited by 376 · see citing works

Vasopressinergic regulation of the hypothalamic–pituitary–adrenal axis: implications for stress adaptation

Aguilera, G., & Rabadan-Diehl, C. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00196-8 · Cited by 375 · see citing works

Extrapituitary expression of the rat V1b vasopressin receptor gene.

Lolait, S. J., O’Carroll, A., Mahan, L. C., Felder, C. C., Button, D. C., Young, W. S., Mezey, É., & Brownstein, M. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6783 · Cited by 337 · see citing works

Oxytocin and Vasopressin V1a and V2 Receptors Form Constitutive Homo- and Heterodimers during Biosynthesis

Terrillon, S., Durroux, T., Mouillac, B., Breit, A., Ayoub, M. A., Taulan‐Cadars, M., Jockers, R., Barberis, C., & Bouvier, M. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0222 · Cited by 323 · see citing works

Comparative Distribution of Vasopressin V1b and Oxytocin Receptor Messenger Ribonucleic Acids in Brain ¹

Vaccari, C., Lolait, S. J., & Ostrowski, N. L. (1998) · Endocrinology · doi:10.1210/endo.139.12.6382 · Cited by 308 · see citing works

Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.

Gal, C. S., Wagnon, J., Garcia, C., Lacour, C., Guiraudou, P., Christophe, B., Villanova, G., Nisato, D., Maffrand, J., & Fur, G. L. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116554 · Cited by 272 · see citing works

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

Gal, C. S., Lacour, C., Valette, G., Garcia, G., Foulon, L., Galindo, G., Bankir, L., Pouzet, B., Guillon, G., Barberis, C., et al. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119098 · Cited by 249 · see citing works

Characterization of (2 S,4 R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V1b Receptor Antagonist

Gal, C. S.-L., Wagnon, J., Simiand, J., Griebel, G., Lacour, C., Guillon, G., Barberis, C., Brossard, G., Soubrié, P., Nisato, D., et al. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1122 · Cited by 211 · see citing works

Cloning and characterization of the human V3 pituitary vasopressin receptor

de Keyzer, Y., Auzan, C., Lenne, F., Beldjord, C., Thibonnier, M., Bertagna, X., & Clauser, E. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)01268-7 · Cited by 209 · see citing works

Molecular Pharmacology of Human Vasopressin Receptors

Thibonnier, M., Conarty, D. M., Preston, J. A., Wilkins, P. L., Berti‐Mattera, L. N., & Mattera, R. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4871-3_34 · Cited by 145 · see citing works

Molecular Cloning and Characterization of Rat V1B Vasopressin Receptor: Evidence for Its Expression in Extrapituitary Tissues

Saito, M., Sugimoto, T., Tahara, A., & Kawashima, H. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2033 · Cited by 124 · see citing works

Vasotocin and vasopressin stimulation of the chloride secretion in the human bronchial epithelial cell line, 16HBE14o‐

Bernard, K. F., Bogliolo, S., & Ehrenfeld, J. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706103 · Cited by 122 · see citing works

Molecular neurobiology and pharmacology of the Vasopressin/Oxytocin receptor family

Burbach, J. P. H., Burbach, H., Adan, R. A. H., Lolait, S. J., van Leeuwen, F. W., Mezey, É., Palkovits, M., & Barberis, C. (1995) · Cellular and Molecular Neurobiology · doi:10.1007/bf02071318 · Cited by 118 · see citing works

Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415

Stemmelin, J., Lukovic, L., Salome, N., & Griebel, G. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300562 · Cited by 112 · see citing works

Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach

Oshikawa, S., Tanoue, A., Koshimizu, T.-A., Kitagawa, Y., & Tsujimoto, G. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.3.623 · Cited by 105 · see citing works

Overexpression of vasopressin (V3) and corticotrophin‐releasing hormone receptor genes in corticotroph tumours

de Keyzer, Y., René, P., Beldjord, C., Lenne, F., & BERTAGNA, X. Y. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00560.x · Cited by 87 · see citing works

Molecular biology of vasopressin receptors

LOLAIT, S. J., O'CARROLL, A., & BROWNSTEIN, M. J. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb44688.x · Cited by 87 · see citing works

1-desamino-8-d-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor

Saito, M., Tahara, A., & Sugimoto, T. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00070-1 · Cited by 82 · see citing works

[1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors

Derick, S., Cheng, L. L., Voirol, M. J., Stoev, S., Giacomini, M., Wo, N. C., Szeto, H. H., Ben Mimoun, M., Andres, M., Gaillard, R. C., et al. (2002) · Endocrinology · doi:10.1210/en.2002-220363 · Cited by 76 · see citing works

Molecular pharmacology of AVP and OT receptors and therapeutic potential

Barberis, C., Morin, D., Durroux, T., Mouillac, B., Guillon, G., Seyer, R., Hibert, M., Tribollet, E., & Manning, M. (1999) · Drug News & Perspectives · doi:10.1358/dnp.1999.12.5.863621 · Cited by 71 · see citing works

Mechanisms of Cell-surface Rerouting of an Endoplasmic Reticulum-retained Mutant of the Vasopressin V1b/V3 Receptor by a Pharmacological Chaperone

Robert, J., Auzan, C., Ventura, M. A., & Clauser, É. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m510180200 · Cited by 66 · see citing works

Properties of rat anterior pituitary vasopressin receptors: relation to adenylate cyclase and the effect of corticotropin-releasing factor.

Gaillard, R.-C., Schoenenberg, P., Favrod-Coune, C. A., Muller, A. F., Marie, J., Bockaert, J., & Jard, S. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.9.2907 · Cited by 64 · see citing works

Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues

Pettibone, D. J., Kishel, M. T., Woyden, C. J., Clineschmidt, B. V., Bock, M. G., Freidinger, R. M., Veber, D. F., & Williams, P. D. (1992) · Life Sciences · doi:10.1016/0024-3205(92)90524-s · Cited by 64 · see citing works

Pancreatic vasopressin V _1b receptors: characterization in In-R1-G9 cells and localization in human pancreas

Folny, V., Raufaste, D., Lukovic, L., Pouzet, B., Rochard, P., Pascal, M., & Serradeil-Le Gal, C. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00148.2003 · Cited by 61 · see citing works

Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist

Griffante, C., Green, A., Curcuruto, O., Haslam, C. P., Dickinson, B. A., & Arban, R. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706383 · Cited by 60 · see citing works

SSR126768A (4-Chloro-3-[(3 R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2- oxo-2,3-dihydro-1 H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, Hydrochloride): A New Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor

Gal, C. S., Valette, G., Foulon, L., Germain, G., Advenier, C., Naline, E., Bardou, M., Martinolle, J.-P., Pouzet, B., Raufaste, D., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.061200 · Cited by 56 · see citing works

Expression of all known vasopressin receptor subtypes by small cell tumors implies a multifaceted role for this neuropeptide.

North, W. G., Fay, M. J., Longo, K. A., & Du, J. (1998) · PubMed · Cited by 55 · see citing works

Plasma corticotropin and cortisol responses to ovine corticotropin- releasing hormone (CRH), arginine vasopressin (AVP), CRH plus AVP, and CRH plus metyrapone in patients with Cushing's disease

Dickstein, G., DEBOLD, C. R., Gaitan, D., DeCherney, G. S., Jackson, R. V., Sheldon, W. R., Nicholson, W. E., & Orth, D. N. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.8.8768855 · Cited by 52 · see citing works

Downregulation of the vasopressin type 2 receptor after vasopressin-induced internalization: involvement of a lysosomal degradation pathway

Bouley, R., Lin, H. Y.-F., Raychowdhury, M. K., Marshansky, V. N., Brown, D., & Ausiello, D. A. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00353.2004 · Cited by 52 · see citing works

Vasopressin Receptors

Jard, S. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4871-3_1 · Cited by 49 · see citing works

Vasopressin and oxytocin

Douglas, A. J. (2005) · Techniques in the behavioral and neural sciences · doi:10.1016/s0921-0709(05)80014-8 · Cited by 48 · see citing works

Vasopressin receptors. A historical survey.

Jard, S. (1998) · PubMed · Cited by 48 · see citing works

Gene and cDNA cloning and characterization of the mouse V3/V1b pituitary vasopressin receptor

Ventura, M., René, P., de Keyzer, Y., BERTAGNA, X. Y., & Clauser, É. (1999) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0220251 · Cited by 45 · see citing works

Vasopressin Receptors in Human Adrenal Medulla and Pheochromocytoma1

Grazzini, E., Breton, C., Derick, S., Andrés, M., Raufaste, D., Rickwaert, F., Boccara, G., Colson, P. H., Guérineau, N. C., Gal, C. S., et al. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.6.5775 · Cited by 44 · see citing works

Characterization of receptors mediating AVP- and OT-induced glucagon release from the rat pancreas

Yibchok‐anun, S., Cheng, H., Heine, P. A., & Hsu, W. H. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.1.e56 · Cited by 42 · see citing works

Binding of [3H] SR 49059, a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranes

Serradeillegal, C., Raufaste, D., Marty, E., Garcia, C., Maffrand, J. P., & Lefur, G. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1236 · Cited by 40 · see citing works

Autoradiographic localization of vasopressin V1a receptors in the rat kidney using [3H]-SR 49059

Gal, C. S., Raufaste, D., Marty, E., Garcia, C., Maffrand, J., & Fur, G. L. (1996) · Kidney International · doi:10.1038/ki.1996.341 · Cited by 36 · see citing works

The Discovery of Novel Vasopressin V1b Receptor Ligands for Pharmacological, Functional and Structural Investigations

Guillon, G., Derick, S., Peña, A., Cheng, L., Stoev, S., Seyer, R., Morgat, J. L., Barberis, C., Gal, C. S., Wagnon, J., et al. (2004) · Journal of Neuroendocrinology · doi:10.1111/j.0953-8194.2004.01163.x · Cited by 35 · see citing works

Reconstitution of the myometrial oxytocin receptor into proteoliposomes

Klein, U., & Fahrenholz, F. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.tb18656.x · Cited by 33 · see citing works

Rapid isolation of highly productive recombinant Chinese hamster ovary cell lines

Miloux, B., & Lupker, J. H. (1994) · Gene · doi:10.1016/0378-1119(94)90173-2 · Cited by 31 · see citing works

Comparison of antagonist activity of spantide family at human neurokinin receptors measured by aequorin luminescence-based functional calcium assay

Janecka, A. E., Poels, J., Fichna, J., Studzian, K., & Broeck, J. V. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2005.05.006 · Cited by 17 · see citing works

Characterization of rodent liver and kidney AVP receptors: pharmacologic evidence for species differences

Tahara, A., Tsukada, J., Ishii, N., Tomura, Y., Wada, K., Kusayama, T., Yatsu, T., Uchida, W., & Tanaka, A. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00059-2 · Cited by 13 · see citing works

Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics

Manning, M., Misicka, A., Olma, A., Bankowski, K., Stoev, S., Chini, B., Durroux, T., Mouillac, B., Corbani, M., & Guillon, G. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02303.x · Cited by 423 · see citing works

Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents☆

MANNING, M., STOEV, S., CHINI, B., DURROUX, T., MOUILLAC, B., & GUILLON, G. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00437-8 · Cited by 296 · see citing works

Cross-talk among oxytocin and arginine-vasopressin receptors: Relevance for basic and clinical studies of the brain and periphery

Song, Z., & Albers, H. E. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.10.004 · Cited by 244 · see citing works

Species, sex and individual differences in the vasotocin/vasopressin system: relationship to neurochemical signaling in the social behavior neural network

Albers, H. E. (2015) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.07.001 · Cited by 200 · see citing works

Neurohypophyseal hormones manipulation modulate social and anxiety-related behavior in zebrafish

Braida, D., Donzelli, A., Martucci, R., Capurro, V., Busnelli, M., Chini, B., & Sala, M. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2482-2 · Cited by 116 · see citing works

The vasopressin Avpr1b receptor: Molecular and pharmacological studies

Roper, J. A., O'Carroll, A.-M., Young, W. S., & Lolait, S. (2010) · Stress · doi:10.3109/10253890.2010.512376 · Cited by 116 · see citing works

Selective and potent agonists and antagonists for investigating the role of mouse oxytocin receptors

Busnelli, M., Bulgheroni, E., Manning, M., Kleinau, G., & Chini, B. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.202994 · Cited by 102 · see citing works

G PROTEIN‐COUPLED RECEPTORS

Alexander, S., Mathie, A. A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_3.x · Cited by 88 · see citing works

Subtle modifications to oxytocin produce ligands that retain potency and improved selectivity across species

Muttenthaler, M., Andersson, Å., Vetter, I., Menon, R., Busnelli, M., Ragnarsson, L. K. N., Bergmayr, C., Arrowsmith, S., Deuis, J. R., Chiu, H. S., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aan3398 · Cited by 79 · see citing works

Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an “easy guide” to receptor pharmacology

CHINI, B., MANNING, M., & GUILLON, G. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00438-x · Cited by 65 · see citing works

Oxytocin and vasopressin signaling in health and disease

Perisic, M., Woolcock, K., Hering, A., Mendel, H. C., & Muttenthaler, M. (2024) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.01.010 · Cited by 40 · see citing works

Acute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V1Areceptors

Taveau, C., Chollet, C., Bichet, D. G., Velho, G., Guillon, G., Corbani, M., Roussel, R., Bankir, L., Melander, O., & Bouby, N. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00269.2016 · Cited by 36 · see citing works

Vasopressin and Oxytocin

Zingg, H. H., Bourque, C. W., & Bichet, D. G. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4871-3 · Cited by 27 · see citing works

The Posterior Pituitary

Bichet, D. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804169-7.00008-8 · Cited by 25 · see citing works

Synthesis of [11C]SSR149415 and preliminary imaging studies using positron emission tomography

Schönberger, M., Leggett, C. S., Kim, S. W., & Hooker, J. M. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.108 · Cited by 24 · see citing works

The effect of vasopressin 1b receptors (V1bRs) blockade on the HPA axis activity in rats exposed to acute heat stress

Jasnic, N. I., Djordjevic, J. D., Vujovic, P. Z., Lakic, I. V., Djurasevic, S. F., & Cvijić, G. (2013) · Journal of Experimental Biology · doi:10.1242/jeb.082842 · Cited by 20 · see citing works

V1bvasopressin receptor trafficking and signaling: Role of arrestins, G proteins and Src kinase

Perkovska, S., Méjean, C., Ayoub, M. A., Li, J., Hemery, F., Corbani, M., Laguette, N., Ventura, M. A., Orcel, H., Durroux, T., et al. (2017) · Traffic · doi:10.1111/tra.12535 · Cited by 14 · see citing works

Exploring the Ligand Recognition Properties of the Human Vasopressin V 1a Receptor Using QSAR and Molecular Modeling Studies

Contreras‐Romo, M. C., Martínez‐Archundia, M., Deeb, O., Ślusarz, M. J., Ramírez-Salinas, G. L., Garduño‐Juárez, R., Quintanar‐Stephano, A., Ramírez‐Galicia, G., & Correa‐Basurto, J. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12229 · Cited by 11 · see citing works

Chapter 6 Advances in Vasopressin Receptor Agonists and Antagonists

Ryckmans, T. (2009) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(09)04406-6 · Cited by 11 · see citing works

Characterization of a functional V1B vasopressin receptor in the male rat kidney: evidence for cross talk between V1B and V2 receptor signaling pathways

Hus-Citharel, A., Bouby, N., Corbani, M., Mion, J., Mendre, C., Darusi, J., Tömböly, C., Trueba, M., Gal, C. S., Llorens‐Cortés, C., et al. (2021) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00081.2021 · Cited by 10 · see citing works

Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer 11C-TASP699

Naganawa, M., Nabulsi, N., Matuskey, D., Henry, S. E., Ropchan, J. R., Lin, S.-F., Gao, H., Pracitto, R., Labaree, D. C., Zhang, M., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262430 · Cited by 10 · see citing works

N-Substituted 3-Aminooxindoles and N-Propargyl Derivatives: Potential Biological Activities against Alzheimer’s Disease

Hofmanova, T., Marques, C. S., García‐Sosa, A. T., López, Ó., Leitzbach, L., Carreiro, E. P., González‐Bakker, A., Puerta, A., Stark, H., Padrón, J. M., et al. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.101032 · Cited by 9 · see citing works

Drug-induced suppression of ACTH secretion does not promote anti-depressive or anxiolytic effects

Ramos, A. T., Homem, K. S. D. C., Suchecki, D., Tufik, S., & Troncone, L. R. P. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.02.024 · Cited by 7 · see citing works

The Posterior Pituitary

Bichet, D. G. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-380926-1.10008-2 · Cited by 6 · see citing works

TASP0434299: A Novel Pyridopyrimidin-4-One Derivative as a Radioligand for Vasopressin V1B Receptor

Koga, K., Yoshinaga, M., Uematsu, Y., Nagai, Y., Miyakoshi, N., Shimoda, Y., Fujinaga, M., Minamimoto, T., Zhang, M.-R., Higuchi, M., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232942 · Cited by 3 · see citing works

Structural Basis for Antagonist Binding to Vasopressin V1b Receptor Revealed by the Molecular Dynamics Simulations

Ślusarz, M. J. (2024) · Biopolymers · doi:10.1002/bip.23627 · Cited by 2 · see citing works

Electrophilic amination reactions with 1 H ‐indazole ‐3‐carboxylates: Synthesis of amino acid frameworks and 3‐amino ‐2‐oxindoles

Mizota, I., Mori, M., & Shimizu, M. (2020) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.4015 · Cited by 2 · see citing works

The Posterior Pituitary

Bichet, D. G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99899-4.00020-2 · Cited by 1 · see citing works

7TM RECEPTORS

(2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00501.x · Cited by 1 · see citing works

Etude des propriétés fonctionnelles de variants de polymorphisme du récepteur V1B de la vasopressine détectés dans les troubles affectifs

Manière, M. (2015) · theses.fr (ABES) · doi:10.70675/0be8e854za3f5z48bcz81c6zbe779562a135 · Cited by 1 · see citing works

Sustained Epigenetic Programming of POMC by Early Life Stress

Wu, Y. (2012) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.13140/2.1.3838.8809

Cross-talk between the Oxytocin and Vasopressin Systems in the Brian: Roles in Social Behavior

Song, Z. (2022) · Digital Archive @ GSU · doi:10.57709/7996120

Vasopressin and oxytocin

Yoshida, H. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00501_64.x

Vasopressin 1A and 1B receptor–mediated antinociception in a mouse model of cortical spreading depolarization

Kwamo, T., Hancock, M., Kaya, M. Z., Olagundoye, F., & Harriott, A. M. (2026) · Pain · doi:10.1097/j.pain.0000000000004025

Copper/Brønsted Acid Cocatalyzed Mannich Reaction of Internal Alkenes with Isatin-Derived Ketimines

Sha, H., Wu, X. Y., Wang, Y. N., Wen, S., Wang, Y., Li, Y. P., Ji, J., & Mou, Y. (2026) · Synthesis · doi:10.1055/a-2919-0278

Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist

Griffante, C., Green, A., Curcuruto, O., Haslam, C. P., Dickinson, B. A., & Arban, R. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706383 · Cited by 60 · see citing works

The Discovery of Novel Vasopressin V1b Receptor Ligands for Pharmacological, Functional and Structural Investigations

Guillon, G., Derick, S., Peña, A., Cheng, L., Stoev, S., Seyer, R., Morgat, J. L., Barberis, C., Gal, C. S., Wagnon, J., et al. (2004) · Journal of Neuroendocrinology · doi:10.1111/j.0953-8194.2004.01163.x · Cited by 35 · see citing works

Characterization of (2 S,4 R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V1b Receptor Antagonist

Gal, C. S.-L., Wagnon, J., Simiand, J., Griebel, G., Lacour, C., Guillon, G., Barberis, C., Brossard, G., Soubrié, P., Nisato, D., et al. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1122 · Cited by 211 · see citing works

Binding of [3H] SR 49059, a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranes

Serradeillegal, C., Raufaste, D., Marty, E., Garcia, C., Maffrand, J. P., & Lefur, G. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1236 · Cited by 40 · see citing works

Functional and Pharmacological Characterization of the First Specific Agonist and Antagonist for the V1b Receptor in Mammals

Claudine, S.-L. G., Derick, S., Brossard, G., Maurice, M., Simiand, J., Rolf, G., Griebel, G., & Guillon, G. (2003) · Stress · doi:10.1080/1025389032000114524 · Cited by 92 · see citing works